Tagged as: Biosimilars Council

House Introduces Bill, BIOSIM Act, Designed To Lower Drug Costs

On April 23, 2021, Congressmen Schrader and Kinzinger introduced H.R. 2815, the Bolstering Innovative Option to Save Immediately on Medicines Act (“BIOSIM Act”).  The bill provides for temporary increased reimbursement to hospitals and doctors for biosimilar drugs from the average sales price (ASP) of the drug plus 6% to the…

Read More

Biosimilars Council: Express Scripts’s National Preferred Flex Formulary is an Opportunity for Biosimilars

Express Scripts has announced “a new drug reimbursement list with lower U.S. prices for brand-name medications, as a way to encourage drugmakers to move away from paying rebates after a prescription is filled.”  You can read Express Scripts’s press release here.  According to the Biosimilars Council, this could provide a particular opportunity…

Read More